Subject(s)
Biomarkers/blood , Biomarkers/urine , Pressure Ulcer/blood , Pressure Ulcer/urine , Spinal Cord Injuries/blood , Spinal Cord Injuries/urine , Animals , Blood Proteins/urine , Disease Models, Animal , Fatty Acid-Binding Proteins/blood , Fatty Acid-Binding Proteins/urine , Female , Glycoproteins/blood , Glycoproteins/urine , Myoglobin/blood , Myoglobinuria/etiology , Myosins/blood , Myosins/urine , Orosomucoid , Rats , Rats, Sprague-Dawley , Troponin I/blood , Troponin I/urineABSTRACT
In this study, we measured cMLC1 concentration in serum and urine from patients with acute myocardial infarction (AMI), chronic renal failure (CRF), and various grades of renal dysfunction (RD) in comparison with normal controls, by using enzyme immunoassay (EIA) with monoclonal antibody, and attempted to elucidate the mechanism of increased serum level of cMLC1 in patients with renal failure. The serum level of cMLC1 of CRF patients under maintenance hemodialysis (HD) was 20.3 +/- 19.6 ng/ml, markedly higher than normal controls (0.54 +/- 0.55 ng/ml). The patients with RD and CRF under conservative therapy had higher serum cMLC1 level than normal controls especially in advanced CRF, while each value not correlating with their creatine clearance (Ccr). cMLC1 in urine was detectable in only two cases with AMI accompanied with CRF or RD. In addition, immunohistological studies of renal biopsy specimens from RD patients did not show cMLC1 deposits in glomerulus. These results suggest that cMLC1 is assumably filtered through the glomerulus, and then absorbed in the renal tubule.
